Dr. Matulewicz explains the need for urologists to promote smoking cessation
“Cigarette smoking and continued smoking exposes patients [with bladder cancer] to a lot of continued risk, and I don't think we're doing our job as a doctor by ignoring this critical part of counseling and education,” says Dr. Matulewicz.
In this interview, Richard S. Matulewicz, MD, MSCI, MS, emphasizes the need for urologists to take a more active role in patient education based on findings from his recent study, “Knowledge of bladder cancer risk factors among patients diagnosed with non–muscle-invasive bladder cancer”. Matulewicz is a urologic oncologist and surgeon at Memorial Sloan Kettering Cancer Center in New York, New York.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
